Latest period
$34.65M
YoY change
+47.5%
5Y CAGR
-22.2%
Peak year (2020)
$149.43M
Latest annual
$42.52M
Total Equity history chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: $42.52M
Total Equity growth chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: +47.5%
Total Equity history table for Spruce Biosciences (SPRB) from 2018 to 2025
| 2025 | $42.52M | +47.5% | +$13.70M | ||
| 2024 | $28.82M | -62.3% | −$47.69M | ||
| 2023 | $76.51M | +11.7% | +$8.02M | ||
| 2022 | $68.49M | -38.5% | −$42.88M | ||
| 2021 | $111.37M | -25.5% | −$38.06M | ||
| 2020 | $149.43M | -587.7% | +$180.06M | ||
| 2019 | −$30.64M | +72.1% | −$12.84M | ||
| 2018 | −$17.80M | — | — |
- 2025$42.52M+47.5%
- 2024$28.82M-62.3%
- 2023$76.51M+11.7%
- 2022$68.49M-38.5%
- 2021$111.37M-25.5%
- 2020$149.43M-587.7%
- 2019−$30.64M+72.1%
- 2018−$17.80M—
Total Equity values are taken from Spruce Biosciences's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Spruce Biosciences (SPRB)
According to Spruce Biosciences's latest reported financial statements, the company's latest reported total equity is $34.65M. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Spruce Biosciences (SPRB) total equity totalled $42.52M – surged 47.5% year-over-year.
Across 2020–2025 (5 years), Spruce Biosciences total equity produced a CAGR of -22.2% – with a net decline across the window.
Spruce Biosciences total equity peaked at $149.43M in 2020; the latest annual figure is $42.52M in 2025 (71.5% below peak).
2020 marks the peak total equity at $149.43M, with the historical low of −$30.64M recorded in 2019.
Spruce Biosciences Total Equity by Year
Spruce Biosciences Total Equity 2025: $42.52M
Spruce Biosciences total equity in 2025 was $42.52M, surged 47.5% from 2024.
Spruce Biosciences Total Equity 2024: $28.82M
2024's total equity for Spruce Biosciences came in at $28.82M, plunged 62.3% below 2023.
Spruce Biosciences Total Equity 2023: $76.51M
Spruce Biosciences posted total equity of $76.51M in 2023, grew 11.7% from 2022.
Spruce Biosciences Total Equity 2022: $68.49M
In 2022, Spruce Biosciences reported total equity of $68.49M, plunged 38.5% below 2021.
Spruce Biosciences Total Equity 2021: $111.37M
Spruce Biosciences total equity in 2021 was $111.37M.
See more financial history for Spruce Biosciences (SPRB).
Sector peers by Total Equity
Healthcare peers of Spruce Biosciences (SPRB), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation